Knockout of epstein-barr virus BPLF1 retards B-cell transformation and lymphoma formation in humanized mice

mBio

Volumn 6, Issue 5, 2015, Pages

  Whitehurst, Christopher B ^a   Li, Guangming ^b   Montgomery, Stephanie A ^a,b   Montgomery, Nathan D ^a   Su, Lishan ^a,b   Paganoa, Joseph S ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BPLF1 PROTEIN; KI 67 ANTIGEN; UNCLASSIFIED DRUG; VIRUS PROTEIN; BPLF1 PROTEIN, EPSTEIN-BARR VIRUS; VIRAL PROTEIN; VIRULENCE FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; CELL TRANSFORMATION; CONTROLLED STUDY; EPSTEIN BARR VIRUS INFECTION; HUMAN; HUMAN CELL; LEUKOCYTE; LYMPHOMA; MOUSE; NEWBORN; NONHUMAN; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; SPLEEN TUMOR; SURVIVAL TIME; T LYMPHOCYTE; TUMOR GROWTH; VIRUS GENOME; VIRUS INFECTIVITY; WEIGHT REDUCTION; ANIMAL; BODY WEIGHT; DEFICIENCY; DISEASE MODEL; EPSTEIN BARR VIRUS; GENE INACTIVATION; GENETICS; PATHOGENICITY; PATHOLOGY; PHYSIOLOGY; SCID MOUSE; SURVIVAL ANALYSIS; VIROLOGY; VIRUS CELL TRANSFORMATION;

ANIMALS; B-LYMPHOCYTES; BODY WEIGHT; CELL TRANSFORMATION, VIRAL; DISEASE MODELS, ANIMAL; GENE KNOCKOUT TECHNIQUES; HERPESVIRUS 4, HUMAN; HUMANS; LYMPHOMA; MICE; MICE, SCID; SPLENIC NEOPLASMS; SURVIVAL ANALYSIS; VIRAL REGULATORY AND ACCESSORY PROTEINS; VIRULENCE FACTORS;

EID: 84946607112     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.01574-15     Document Type: Article

References (66)

1. MacMahon E, Glass JD, Hayward SD, Mann RB, Becker PS, Charache P, McArthur J, Ambinder RF. 1991. Epstein-Barr virus in AIDS-related primary central nervous system lymphoma. Lancet 338:969-973. http://dx.doi.org/10.1016/0140-6736(91)91837-K.
2. Zhang L, Zhang J, Lambert Q, Der CJ, Del Valle L, Miklossy J, Khalili K, Zhou Y, Pagano JS. 2004. Interferon regulatory factor 7 is associated with Epstein-Barr virus-transformed central nervous system lymphoma and has oncogenic properties. J Virol 78:12987-12995. http://dx.doi.org/10.1128/JVI.78.23.12987-12995.2004.
3. Weiss LM, Movahed LA, Warnke RA, Sklar J. 1989. Detection of Epstein-Barr viral genomes in Reed-Sternberg cells of Hodgkin’s disease. N Engl J Med 320:502-506. http://dx.doi.org/10.1056/NEJM198902233200806.
4. Raab-Traub N. 1992. Epstein-Barr virus and nasopharyngeal carcinoma. Semin Cancer Biol 3:297-307.
5. Zur Hausen HZ, Schulte-Holthausen H, Klein G, Henle W, Henle G, Clifford P, Santesson L. 1970. EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx. Nature 228:1056-1058. http://dx.doi.org/10.1038/2281056a0.
6. Wang F-, Roy D, Gershburg E, Whitehurst CB, Dittmer DP, Pagano JS. 2009. Maribavir inhibits Epstein-Barr virus transcription in addition to viral DNA replication. J Virol 83:12108-12117. http://dx.doi.org/10.1128/JVI.01575-09.
7. Whitehurst CB, Sanders MK, Law M, Wang F-, Xiong J, Dittmer DP, Pagano JS. 2013. Maribavir inhibits Epstein-Barr virus transcription through the EBV protein kinase. J Virol 87:5311-5315. http://dx.doi.org/10.1128/JVI.03505-12.
8. Hong GK, Gulley ML, Feng W-, Delecluse H-, Holley-Guthrie E, Kenney SC. 2005. Epstein-Barr virus lytic infection contributes to lymphoproliferative disease in a SCID mouse model. J Virol 79:13993-14003. http://dx.doi.org/10.1128/JVI.79.22.13993-14003.2005.
9. Jones RJ, Seaman WT, Feng W, Barlow E, Dickerson S, Delecluse H, Kenney SC. 2007. Roles of lytic viral infection and IL-6 in early versus late passage lymphoblastoid cell lines and EBV-associated lymphzoproliferative disease. Int J Cancer 121:1274-1281. http://dx.doi.org/10.1002/ijc.22839.
10. Ma S-, Hegde S, Young KH, Sullivan R, Rajesh D, Zhou Y, Jankowska-Gan E, Burlingham WJ, Sun X, Gulley ML, Tang W, Gumperz JE, Kenney SC. 2011. A new model of Epstein-Barr virus infection reveals an important role for early lytic viral protein expression in the development of lymphomas. J Virol 85:165-177. http://dx.doi.org/10.1128/JVI.01512-10.
11. Batchelor AH, O’Hare P. 1990. Regulation and cell-type-specific activity of a promoter located upstream of the latency-associated transcript of herpes simplex virus type 1. J Virol 64:3269-3279.
12. Kitagawa N, Goto M, Kurozumi K, Maruo S, Fukayama M, Naoe T, Yasukawa M, Hino K, Suzuki T, Todo S, Takada K. 2000. Epstein-Barr virus-encoded poly(A) (-) RNA supports Burkitt’s lymphoma growth through interleukin-10 induction. EMBO J 19:6742-6750. http://dx.doi.org/10.1093/emboj/19.24.6742.
13. Mahot S, Sergeant A, Drouet E, Gruffat H. 2003. A novel function for the Epstein-Barr virus transcription factor EB1/Zta: induction of transcription of the hIL-10 gene. J Gen Virol 84:965-974. http://dx.doi.org/10.1099/vir.0.18845-0.
14. Masood R, Zhang Y, Bond MW, Scadden DT, Moudgil T, Law RE, Kaplan MH, Jung B, Espina BM, Lunardi-Iskandar Y. 1995. Interleukin-10 is an autocrine growth factor for acquired immunodeficiency syndrome-related B-cell lymphoma. Blood 85:3423-3430.
15. Penkert RR, Kalejta RF. 2011. Tegument protein control of latent herpesvirus establishment and animation. Herpesviridae 2:3. http://dx.doi.org/10.1186/2042-4280-2-3.
16. Altmann M, Hammerschmidt W. 2005. Epstein-Barr virus provides a new paradigm: a requirement for the immediate inhibition of apoptosis. PLoS Biol 3:e404. http://dx.doi.org/10.1371/journal.pbio.0030404.
17. Bellows DS, Howell M, Pearson C, Hazlewood SA, Hardwick JM. 2002. Epstein-Barr virus BALF1 is a BCL-2-like antagonist of the herpesvirus antiapoptotic BCL-2 proteins. J Virol 76:2469-2479. http://dx.doi.org/10.1128/jvi.76.5.2469-2479.2002.
18. Oudejans JJ, van den Brule AJ, Jiwa NM, de Bruin PC, Ossenkoppele GJ, van der Valk P, Walboomers JM, Meijer CJ. 1995. BHRF1, the Epstein-Barr virus (EBV) homologue of the BCL-2 protooncogene, is transcribed in EBV-associated B-cell lymphomas and in reactive lymphocytes. Blood 86:1893-1902.
19. Feederle R, Neuhierl B, Baldwin G, Bannert H, Hub B, Mautner J, Behrends U, Delecluse HJ. 2006. Epstein-Barr virus BNRF1 protein allows efficient transfer from the endosomal compartment to the nucleus of primary B lymphocytes. J Virol 80:9435-9443. http://dx.doi.org/10.1128/JVI.00473-06.
20. Tsai K, Chan L, Gibeault R, Conn K, Dheekollu J, Domsic J, Marmorstein R, Schang LM, Lieberman PM. 2014. Viral reprogramming of the Daxx histone H3.3 chaperone during early Epstein-Barr virus infection. J Virol 88:14350-14363. http://dx.doi.org/10.1128/JVI.01895-14.
21. Tsai K, Thikmyanova N, Wojcechowskyj JA, Delecluse H, Lieberman PM. 2011. EBV tegument protein BNRF1 disrupts DAXX-ATRX to activate viral early gene transcription. PLoS Pathog 7:e1002376. http://dx.doi.org/10.1371/journal.ppat.1002376.
22. Baldick CJ, Jr, Marchini A, Patterson CE, Shenk T. 1997. Human cytomegalovirus tegument protein pp71 (ppUL82) enhances the infectivity of viralDNAand accelerates the infectious cycle. J Virol 71:4400-4408.
23. Werstuck G, Bilan P, Capone JP. 1990. Enhanced infectivity of herpes simplex virus type 1 viral DNA in a cell line expressing the trans-inducing factor Vmw65. J Virol 64:984-991.
24. Schmaus S, Wolf H, Schwarzmann F. 2004. The reading frame BPLF1 of Epstein-Barr virus: a homologue of herpes simplex virus protein VP16. VirusGenes 29: 267-277. http://dx.doi.org/10.1023/B:VIRU.0000036387.39937.9b.
25. Gastaldello S, Hildebrand S, Faridani O, Callegari S, Palmkvist M, Di Guglielmo C, Masucci MG. 2010. A deneddylase encoded by Epstein-Barr virus promotes viral DNA replication by regulating the activity of cullin-RING ligases. Nat Cell Biol 12:351-361. http://dx.doi.org/10.1038/ncb2035.
26. Yuan J, Cahir-McFarland E, Zhao B, Kieff E. 2006. Virus and cell RNAs expressed during Epstein-Barr virus replication. J Virol 80:2548-2565. http://dx.doi.org/10.1128/JVI.80.5.2548-2565.2006.
27. Bottcher S, Granzow H, Maresch C, Mohl B, Klupp BG, Mettenleiter TC. 2007. Identification of functional domains within the essential large tegument protein pUL36 of pseudorabies virus. J Virol 81:13403-13411. http://dx.doi.org/10.1128/JVI.01643-07.
28. Desai PJ. 2000. A null mutation in the UL36 gene of herpes simplex virus type 1 results in accumulation of unenveloped DNA-filled capsids in the cytoplasm of infected cells. J Virol 74:11608-11618. http://dx.doi.org/10.1128/JVI.74.24.11608-11618.2000.
29. Batterson W, Furlong D, Roizman B. 1983. Molecular genetics of herpes simplex virus. VIII. Further characterization of a temperature-sensitive mutant defective in release of viral DNA and in other stages of the viral reproductive cycle. J Virol 45:397-407.
30. Abaitua F, Daikoku T, Crump CM, Bolstad M, O’Hare P. 2011. A single mutation responsible for temperature-sensitive entry and assembly defects in the VP1-2 protein of herpes simplex virus. J Virol 85:2024-2036. http://dx.doi.org/10.1128/JVI.01895-10.
31. Whitehurst CB, Ning S, Bentz GL, Dufour F, Gershburg E, Shackelford J, Langelier Y, Pagano JS. 2009. The Epstein-Barr virus (EBV) deubiquitinating enzyme BPLF1 reduces EBV ribonucleotide reductase activity. J Virol 83:4345-4353. http://dx.doi.org/10.1128/JVI.02195-08.
32. Kattenhorn LM, Korbel GA, Kessler BM, Spooner E, Ploegh HL. 2005. A deubiquitinating enzyme encoded by HSV-1 belongs to a family of cysteine proteases that is conserved across the family Herpesviridae. Mol Cell 19:547-557. http://dx.doi.org/10.1016/j.molcel.2005.07.003.
33. Ernst R, Claessen JHL, Mueller B, Sanyal S, Spooner E, van der Veen AG, Kirak O, Schlieker CD, Weihofen WA, Ploegh HL. 2011. Enzymatic blockade of the ubiquitin-proteasome pathway. PLoS Biol 8:e1000605. http://dx.doi.org/10.1371/journal.pbio.1000605.
34. Inn K-, Lee S-, Rathbun JY, Wong L-, Toth Z, Machida K, Ou JJ, Jung JU. 2011. Inhibition of RIG-I-mediated signaling by Kaposi’s sarcomaassociated herpesvirus-encoded deubiquitinase ORF64. J Virol 85: 10899-10904. http://dx.doi.org/10.1128/JVI.00690-11.
35. Wang J, Loveland AN, Kattenhorn LM, Ploegh HL, Gibson W. 2006. High-molecular-weight protein (pUL48) of human cytomegalovirus is a competent deubiquitinating protease: mutant viruses altered in its activesite cysteine or histidine are viable. J Virol 80:6003-6012. http://dx.doi.org/10.1128/JVI.00401-06.
36. Gredmark-Russ S, Isaacson MK, Kattenhorn L, Cheung EJ, Watson N, Ploegh HL. 2009. A gammaherpesvirus ubiquitin-specific protease is involved in the establishment of murine gammaherpesvirus 68 infection. J Virol 83:10644-10652. http://dx.doi.org/10.1128/JVI.01017-09.
37. Bottcher S, Maresch C, Granzow H, Klupp BG, Teifke JP, Mettenleiter TC. 2008. Mutagenesis of the active-site cysteine in the ubiquitin-specific protease contained in large tegument protein pUL36 of pseudorabies virus impairs viral replication in vitro and neuroinvasion in vivo. J Virol 82: 6009-6016. http://dx.doi.org/10.1128/JVI.00280-08.
38. Kim ET, Oh SE, Lee Y-O, Gibson W, Ahn J-H. 2009. Cleavage specificity of the UL48 deubiquitinating protease activity of human cytomegalovirus and the growth of an active-site mutant virus in cultured cells. J Virol 83:12046-12056. http://dx.doi.org/10.1128/JVI.00411-09.
39. Jarosinski K, Kattenhorn L, Kaufer B, Ploegh H, Osterrieder N. 2007. A herpesvirus ubiquitin-specific protease is critical for efficient T cell lymphoma formation. Proc Natl Acad Sci U S A 104:20025-20030. http://dx.doi.org/10.1073/pnas.0706295104.
40. Ma S-, Yu X, Mertz JE, Gumperz JE, Reinheim E, Zhou Y, Tang W, Burlingham WJ, Gulley ML, Kenney SC. 2012. An Epstein-Barr virus (EBV) mutant with enhanced BZLF1 expression causes lymphomas with abortive lytic EBV infection in a humanized mouse model. J Virol 86: 7976-7987. http://dx.doi.org/10.1128/JVI.00770-12.
41. Wahl A, Linnstaedt SD, Esoda C, Krisko JF, Martinez-Torres F, Delecluse H-, Cullen BR, Garcia JV. 2013. A cluster of virus-encoded microRNAs accelerates acute systemic Epstein-Barr virus infection but does not significantly enhance virus-induced oncogenesis in vivo. J Virol 87: 5437-5446. http://dx.doi.org/10.1128/JVI.00281-13.
42. Fujiwara S, Imadome K, Takei M. 2015. Modeling EBV infection and pathogenesis in new-generation humanized mice. Exp Mol Med 47:e135. http://dx.doi.org/10.1038/emm.2014.88.
43. Antsiferova O, Müller A, Rämer PC, Chijioke O, Chatterjee B, Raykova A, Planas R, Sospedra M, Shumilov A, Tsai M, Delecluse H, Münz C. 2014. Adoptive transfer of EBV specific CD8_T cell clones can transiently control EBV infection in humanized mice. PLoS Pathog 10:e1004333. http://dx.doi.org/10.1371/journal.ppat.1004333.
44. Chatterjee B, Leung CS, Münz C. 2014. Animal models of Epstein-Barr virus infection. J Immunol Methods 410:80-87. http://dx.doi.org/10.1016/j.jim.2014.04.009.
45. Fujiwara S. 2014. Reproduction of Epstein-Barr virus infection and pathogenesis in humanized mice. Immune Netw 14:1-6. http://dx.doi.org/10.4110/in.2014.14.1.1.
46. Jiang Q, Zhang L, Wang R, Jeffrey J, Washburn ML, Brouwer D, Barbour S, Kovalev GI, Unutmaz D, Su L. 2008. FoxP3_CD4_regulatory T cells play an important role in acute HIV-1 infection in humanized Rag2_/_gammaC_/_mice in vivo. Blood 112:2858-2868. http://dx.doi.org/10.1182/blood-2008-03-145946.
47. Zhang L, Kovalev GI, Su L. 2007. HIV-1 infection and pathogenesis in a novel humanized mouse model. Blood 109:2978-2981. http://dx.doi.org/10.1182/blood-2006-07-033159.
48. Saito S, Murata T, Kanda T, Isomura H, Narita Y, Sugimoto A, Kawashima D, Tsurumi T. 2013. Epstein-Barr virus deubiquitinase downregulates TRAF6-mediated NF-kappaB signaling during productive replication. J Virol 87:4060-4070. http://dx.doi.org/10.1128/JVI.02020-12.
49. Delecluse H-, Hilsendegen T, Pich D, Zeidler R, Hammerschmidt W. 1998. Propagation and recovery of intact, infectious Epstein-Barr virus from prokaryotic to human cells. Proc Natl Acad Sci U S A 95:8245-8250. http://dx.doi.org/10.1073/pnas.95.14.8245.
50. Gastaldello S, Hildebrand S, Faridani O, Callegari S, Palmkvist M, Di Guglielmo C, Masucci MG. 2010. A deneddylase encoded by Epstein-Barr virus promotes viral DNA replication by regulating the activity of cullin-RING ligases. Nat Cell Biol 12:351-361. http://dx.doi.org/10.1038/ncb2035.
51. Hong GK, Delecluse H-, Gruffat H, Morrison TE, Feng W-, Sergeant A, Kenney SC. 2004. The BRRF1 early gene of Epstein-Barr virus encodes a transcription factor that enhances induction of lytic infection by BRLF1. J Virol 78:4983-4992. http://dx.doi.org/10.1128/JVI.78.10.4983-4992.2004.
52. Kumar R, Whitehurst CB, Pagano JS. 2014. The Rad6/18 ubiquitin complex interacts with the Epstein-Barr virus deubiquitinating enzyme, BPLF1, and contributes to virus infectivity. J Virol 88:6411-6422. http://dx.doi.org/10.1128/JVI.00536-14.
53. Henle W, Diehl V, Kohn G, Zur Hausen H, Henle G. 1967. Herpes-type virus and chromosome marker in normal leukocytes after growth with irradiated Burkitt cells. Science 157:1064-1065. http://dx.doi.org/10.1126/science.157.3792.1064.
54. Whitehurst CB, Vaziri C, Shackelford J, Pagano JS. 2012. Epstein-Barr virus BPLF1 deubiquitinates PCNA and attenuates polymerase eta recruitment to DNA damage sites. J Virol 86:8097-8106. http://dx.doi.org/10.1128/JVI.00588-12.
55. Van Gent M, Braem SGE, de Jong A, Delagic N, Peeters JGC, Boer IGJ, Moynagh PN, Kremmer E, Wiertz EJ, Ovaa H, Griffin BD, Ressing ME. 2014. Epstein-Barr virus large tegument protein BPLF1 contributes to innate immune evasion through interference with Toll-like receptor sig-naling. PLoS Pathog 10:e1003960. http://dx.doi.org/10.1371/journal.ppat.1003960.
56. Johannsen E, Luftig M, Chase MR, Weicksel S, Cahir-McFarland E, Illanes D, Sarracino D, Kieff E. 2004. Proteins of purified Epstein-Barr virus. Proc Natl Acad Sci U S A 101:16286-16291. http://dx.doi.org/10.1073/pnas.0407320101.
57. Gastaldello S, Chen X, Callegari S, Masucci MG. 2013. Caspase-1 promotes Epstein-Barr virus replication by targeting the large tegument protein deneddylase to the nucleus of productively infected cells. PLoS Pathog 9:e1003664. http://dx.doi.org/10.1371/journal.ppat.1003664.
58. Hurley EA, Thorley-Lawson DA. 1988. B cell activation and the establishment of Epstein-Barr virus latency. J Exp Med 168:2059-2075. http://dx.doi.org/10.1084/jem.168.6.2059.
59. Tomkinson B, Robertson E, Kieff E. 1993. Epstein-Barr virus nuclear proteins EBNA-3A and EBNA-3C are essential for B-lymphocyte growth transformation. J Virol 67:2014-2025.
60. Kaye KM, Izumi KM, Kieff E. 1993. Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proc Natl Acad SciUSA90:9150-9154. http://dx.doi.org/10.1073/pnas.90.19.9150.
61. Sugden B, Marsh K, Yates J. 1985. A vector that replicates as a plasmid and can be efficiently selected in B-lymphoblasts transformed by Epstein-Barr virus. Mol Cell Biol 5:410-413.
62. Yates J, Warren N, Reisman D, Sugden B. 1984. A cis-acting element from the Epstein-Barr viral genome that permits stable replication of recombinant plasmids in latently infected cells. Proc Natl Acad Sci U S A 81:3806-3810. http://dx.doi.org/10.1073/pnas.81.12.3806.
63. Longnecker R, Miller CL, Miao XQ, Tomkinson B, Kieff E. 1993. The last seven transmembrane and carboxy-terminal cytoplasmic domains of Epstein-Barr virus latent membrane protein 2 (LMP2) are dispensable for lymphocyte infection and growth transformation in vitro. J Virol 67: 2006-2013.
64. Tomkinson B, Kieff E. 1992. Use of second-site homologous recombination to demonstrate that Epstein-Barr virus nuclear protein 3B is not important for lymphocyte infection or growth transformation in vitro. J Virol 66:2893-2903.
65. Chen A, Divisconte M, Jiang X, Quink C, Wang F. 2005. Epstein-Barr virus with the latent infection nuclear antigen 3B completely deleted is still competent for B-cell growth transformation in vitro. J Virol 79: 4506-4509. http://dx.doi.org/10.1128/JVI.79.7.4506-4509.2005.
66. Halder S, Murakami M, Verma SC, Kumar P, Yi F, Robertson ES. 2009. Early events associated with infection of Epstein-Barr virus infection of primary B-cells. PLoS One 4:e7214. http://dx.doi.org/10.1371/journal.pone.0007214.